Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C

Journal of Hepatology

Volumn 66, Issue 5, 2017, Pages 888-896

  Langhans, Bettina ^a   Nischalke, Hans Dieter ^a   Krämer, Benjamin ^a   Hausen, Annekristin ^a   Dold, Leona ^a   van Heteren, Peer ^a   Hüneburg, Robert ^a   Nattermann, Jacob ^a   Strassburg, Christian P ^a   Spengler, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

CD4+ regulatory T cells; Chronic hepatitis C virus infection; Directly acting antivirals; Tim 3 galectin 9 pathway

Indexed keywords

ANTIVIRUS AGENT; CD134 ANTIGEN; CD4 ANTIGEN; DACLATASVIR; GLYCOPROTEIN; GLYCOPROTEIN A; INTERLEUKIN 2 RECEPTOR ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GALECTIN; LGALS9 PROTEIN, HUMAN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DOSE RESPONSE; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMAN; LONG TERM CARE; MALE; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRAL CLEARANCE; BLOOD; HEPATITIS C, CHRONIC; IMMUNOLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GALECTINS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 85011311015     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.12.019     Document Type: Article

References (42)

1. [1] Mohd Hanafiah, K., Groeger, J., Flaxman, A.D., Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 (2013), 1333–1342.
2. [2] Spengler, U., Nischalke, H.D., Nattermann, J., Strassburg, C.P., Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol 19 (2013), 7852–7866.
3. [3] Barjon, C., Dahlqvist, G., Calmus, Y., Conti, F., Role of regulatory T-cells during hepatitis C infection: From the acute phase to post-transplantation recurrence. Dig Liver Dis 47 (2015), 913–917.
4. [4] Cabrera, R., Tu, Z., Xu, Y., Firpi, R.J., Rosen, H.R., Liu, C., et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40 (2004), 1062–1071.
5. [5] Sugimoto, K., Ikeda, F., Stadanlick, J., Nunes, F.A., Alter, H.J., Chang, K.-M., Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38 (2003), 1437–1448.
6. [6] Boettler, T., Spangenberg, H.C., Neumann-Haefelin, C., Panther, E., Urbani, S., Ferrari, C., et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 79 (2005), 7860–7867.
7. [7] Langhans, B., Braunschweiger, I., Arndt, S., Schulte, W., Satoguina, J., Layland, L.E., et al. Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci 2010 (1979), 97–109.
8. [8] Langhans, B., Alwan, A.W., Krämer, B., Glässner, A., Lutz, P., Strassburg, C.P., et al. Regulatory CD4+ T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type. J Hepatol 62 (2015), 398–404.
9. + regulatory T cells and fibrogenesis in chronic hepatitis C. J Hepatol 59 (2013), 229–235.
10. [10] Langhans, B., Spengler, U., Reply to: “Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections”. J Hepatol 60 (2014), 232–234.
11. [11] Zhao, H.-Q., Li, W.-M., Lu, Z.-Q., Yao, Y.-M., Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 20 (2014), 7971–7978.
12. [12] Shevach, E.M., Thornton, A.M., TTregs, pTregs, and iTregs: similarities and differences. Immunol Rev 259 (2014), 88–102.
13. [13] Thornton, A.M., Korty, P.E., Tran, D.Q., Wohlfert, E.A., Murray, P.E., Belkaid, Y., et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010 (1950), 3433–3441.
14. [14] Wang, F., Wan, L., Zhang, C., Zheng, X., Li, J., Chen, Z.K., Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. Immunobiology 214 (2009), 342–349.
15. [15] Dilek, N., Poirier, N., Hulin, P., Coulon, F., Mary, C., Ville, S., et al. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PLoS One, 8, 2013, e83139.
16. [16] Au, J.S., Pockros, P.J., Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 95 (2014), 78–88.
17. [17] Pawlotsky, J.-M., New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146 (2014), 1176–1192.
18. [18] Marshall, H.D., Urban, S.L., Welsh, R.M., Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J Virol 85 (2011), 5929–5939.
19. [19] Odorizzi, P.M., Wherry, E.J., Immunology. An interferon paradox. Science 340 (2013), 155–156.
20. [20] Martin, B., Hennecke, N., Lohmann, V., Kayser, A., Neumann-Haefelin, C., Kukolj, G., et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 61 (2014), 538–543.
21. [21] Spaan, M., van Oord, G., Kreefft, K., Hou, J., Hansen, B.E., Janssen, H.L.A., et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Infect Dis 213 (2015), 216–223.
22. [22] Serti, E., Chepa-Lotrea, X., Kim, Y.J., Keane, M., Fryzek, N., Liang, T.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200.
23. [23] Claassen, M.A.A., de Knegt, R.J., Janssen, H.L.A., Boonstra, A., Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans. J Virol 85 (2011), 5323–5330.
24. [24] Spaan, M., Claassen, M.A.A., Hou, J., Janssen, H.L.A., de Knegt, R.J., Boonstra, A., The intrahepatic T cell compartment does not normalize years after therapy-induced hepatitis C virus eradication. J Infect Dis 212 (2015), 386–390.
25. [25] Claassen, M.A.A., de Knegt, R.J., Tilanus, H.W., Janssen, H.L.A., Boonstra, A., Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol 52 (2010), 315–321.
26. [26] Wang, J., Ioan-Facsinay, A., van der Voort, E.I.H., Huizinga, T.W.J., Toes, R.E.M., Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 37 (2007), 129–138.
27. [27] Sakaguchi, S., Miyara, M., Costantino, C.M., Hafler, D.A., FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10 (2010), 490–500.
28. [28] Piconese, S., Pacella, I., Timperi, E., Barnaba, V., Divergent effects of type-I interferons on regulatory T cells. Cytokine Growth Factor Rev 26 (2015), 133–141.
29. [29] Hori, S., Regulatory T cell plasticity: beyond the controversies. Trends Immunol 32 (2011), 295–300.
30. [30] Bailey-Bucktrout, S.L., Bluestone, J.A., Regulatory T cells: stability revisited. Trends Immunol 32 (2011), 301–306.
31. [31] Mengshol, J.A., Golden-Mason, L., Arikawa, T., Smith, M., Niki, T., McWilliams, R., et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS ONE, 5, 2010, e9504.
32. [32] Monney, L., Sabatos, C.A., Gaglia, J.L., Ryu, A., Waldner, H., Chernova, T., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415 (2002), 536–541.
33. [33] Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6 (2005), 1245–1252.
34. [34] Lee, J., Suh, W.I., Shin, E.-C., T-cell dysfunction and inhibitory receptors in hepatitis C virus infection. Immune Netw 10 (2010), 120–125.
35. [35] McMahan, R.H., Golden-Mason, L., Nishimura, M.I., McMahon, B.J., Kemper, M., Allen, T.M., et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 120 (2010), 4546–4557.
36. [36] Moorman, J.P., Wang, J.M., Zhang, Y., Ji, X.J., Ma, C.J., Wu, X.Y., et al. Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J Immunol 2012 (1950), 755–766.
37. [37] Yu, M.L., Lin, S.M., Lee, C.M., Dai, C.Y., Chang, W.Y., Chen, S.C., et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 44 (2006), 1086–1097.
38. [38] Morgan, T.R., Ghany, M.G., Kim, H.Y., Snow, K.K., Shiffman, M.L., De Santo, J.L., et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52 (2010), 833–844.
39. [39] Van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
40. [40] Yoshizawa, K., Abe, H., Kubo, Y., Kitahara, T., Aizawa, R., Matsuoka, M., et al. Expansion of CD4(+)CD25(+)FoxP3(+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. Hepatol Res 40 (2010), 179–187.
41. [41] Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
42. [42] Kozbial, K., Moser, S., Schwarzer, R., Laferl, H., Al-Zoairy, R., Stauber, R., et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment. J Hepatol 65 (2016), 856–868.